2μg (R: reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | IL-13 R alpha 2, CD213A2, CT19, IL-13R, IL13BP |
| Accession | Q14627 |
| Amino Acid Sequence | Asp27-Arg343 with His Tag at the C-Terminus |
| Expression System | CHO |
| Molecular Weight | 40-55kDa (Reducing) |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1. Brown C E, Hibbard J C, Alizadeh D, et al. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial[J]. Nature Medicine, 2024, 30(4): 1001-1012. |
Background
Interleukin-13 receptor α2 (IL-13Rα2), also designated CD213a2, is the high-affinity receptor subunit for IL-13. It is a type I monomeric transmembrane glycoprotein whose extracellular region comprises three fibronectin type III-like domains and a short cytoplasmic tail lacking canonical signaling motifs. IL-13Rα2 binds IL-13 with roughly 50-fold higher affinity than IL-13Rα1 and has traditionally been regarded as a decoy receptor that sequesters IL-13 and suppresses IL-13Rα1/IL-4Rα–STAT6 signaling. Emerging evidence, however, indicates that in specific cellular contexts it can actively signal through STAT6, AP-1, and MAPK/ERK pathways, contributing to epithelial–mesenchymal transition, fibrosis, and tumor progression. IL-13Rα2 is overexpressed in glioblastoma, diffuse midline glioma, pancreatic cancer, colorectal cancer, and hepatocellular carcinoma, making it an attractive tumor-associated antigen. Clinically, IL-13Rα2-directed CAR-T cells—including bivalent EGFR/IL-13Rα2 constructs—IL-13-PE38 immunotoxins, nanobodies, and vaccines have entered clinical or preclinical development. The receptor is also implicated in Th2 inflammation, fibrotic remodeling, and inflammatory bowel disease, and its context-dependent biology continues to inform target selection and therapeutic design.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of IL-13RA2 His Tag Protein, Human is more than 95% determined by SEC-HPLC.
ELISA
Immobilized IL-13 Fc Chimera Protein, Human (Cat. No. UA016182) at 5 μg/mL (100 μL/well) can bind IL-13RA2 His Tag Protein, Human (Cat. No. UA016190) with a linear range of 6.3-7.2 ng/mL.
Immobilized IL-13RA2 His Tag Protein, Human (Cat. No.UA016190) at 1 μg/mL (100 μL/well) can bind IL-13RA2/CD213a2 Rabbit Polyclonal Antibody with a linear range of 1.8-2.4 ng/mL.
Immobilized IL-13RA2/CD213a2 Rabbit Polyclonal Antibody (Cat. No.S0B1131) at 1 μg/mL (100 μL/well) can bind IL-13RA2 His Tag Protein, Human(Cat. No.UA016190) with a linear range of 25-40 ng/mL.
